Nuclear Imaging and Biomarkers in Drug Development Using Approved Radiopharmaceuticals
The 2000 Alfred P. Wolf Award
18FDG for the Study of Central Nervous System Drugs
Can [15O]Water Be Used to Evaluate Drugs?
Prospects for Human Pharmacological Functional Magnetic Resonance Imaging (phMRI)
Reversal of Multidrug Resistance with LY335979
99mTc-Tetrofosmin for Functional Imaging of P-glycoprotein Modulation In Vivo
P-glycoprotein at the Blood-Brain Barrier and Analysis of Drug Transport with Positron-Emission Tomography
The Use of MicroPET for the Development of Neural Repair Therapeutics
Neuroimaging and Drug Development
Monitoring Disease Progression in Parkinson's Disease
Immunological and Molecular Analysis of the Sentinel Lymph Node
Serotonin 5-HT1A Receptor Imaging in the Human Brain with Positron-Emission Tomography
Imaging Cellular Proliferation as a Measure of Response to Therapy
Measurement of Tumor Response Using [18F]-2-Fluoro-2-Deoxy-D-Glucose and Positron-Emission Tomography
Positron-Emission Tomography Tracers as Intellectual Property
The Molecular Imaging Branch of NIMH
Licensing and Distribution of Research Tools
The Patenting of Tools for Drug Discovery and Development
Neuroimaging Consortium Workshop
The Use of Imaging as Biomarkers in Drug Development
Submission of Images to the Center for Biologics Evaluation and Research in Support of License Applications for Therapeutic Agents
Regulation of the Production and Use of Radiopharmaceuticals in Germany and Europe
Regulatory Aspects of Nuclear Imaging in Neuropharmacology
Nonimaging Detectors in Drug Development and Approval